MX419976B - Anticuerpos de tgfb, métodos, y usos - Google Patents

Anticuerpos de tgfb, métodos, y usos

Info

Publication number
MX419976B
MX419976B MX2019000514A MX2019000514A MX419976B MX 419976 B MX419976 B MX 419976B MX 2019000514 A MX2019000514 A MX 2019000514A MX 2019000514 A MX2019000514 A MX 2019000514A MX 419976 B MX419976 B MX 419976B
Authority
MX
Mexico
Prior art keywords
garp
selective antibodies
antigen
binding fragments
protgfβ1 complex
Prior art date
Application number
MX2019000514A
Other languages
English (en)
Other versions
MX2019000514A (es
Inventor
Gregory J Carven
Katherine Turner
Thomas Schurpf
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of MX2019000514A publication Critical patent/MX2019000514A/es
Publication of MX419976B publication Critical patent/MX419976B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se pueden usar anticuerpos selectivos del complejo GARP-proTGFß1, polinucleotidos capaces de codificar los anticuerpos o fragmentos de union al antigeno selectivos del complejo GARP-proTGFß1, celulas que expresan anticuerpos o fragmentos de union al antigeno selectivos del complejo GARP-proTGFß1, asi como vectores asociados y anticuerpos y fragmentos de union al antigeno selectivos del complejo GARP-proTGFß1 marcados detectables para mejorar una respuesta inmune en un sujeto, por ejemplo, contra un cancer.
MX2019000514A 2016-07-14 2017-07-14 Anticuerpos de tgfb, métodos, y usos MX419976B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362393P 2016-07-14 2016-07-14
US201662371355P 2016-08-05 2016-08-05
PCT/US2017/042162 WO2018013939A1 (en) 2016-07-14 2017-07-14 Tgfb antibodies, methods, and uses

Publications (2)

Publication Number Publication Date
MX2019000514A MX2019000514A (es) 2019-07-12
MX419976B true MX419976B (es) 2025-01-14

Family

ID=60953402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000514A MX419976B (es) 2016-07-14 2017-07-14 Anticuerpos de tgfb, métodos, y usos

Country Status (13)

Country Link
US (2) US20190292254A1 (es)
EP (1) EP3484499A4 (es)
JP (2) JP7128801B2 (es)
KR (1) KR102577551B1 (es)
CN (1) CN110049773A (es)
AU (1) AU2017294772B2 (es)
BR (1) BR112019000621A2 (es)
CA (1) CA3030862A1 (es)
IL (1) IL264161B2 (es)
MA (1) MA45690A (es)
MX (1) MX419976B (es)
SG (1) SG11201900200XA (es)
WO (1) WO2018013939A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014298373B2 (en) 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
BR112018068340A2 (pt) 2016-03-11 2019-01-15 Scholar Rock Inc imunoglobulinas de ligação ao tgfss1 e usos destas
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
US11130803B2 (en) 2018-07-11 2021-09-28 Scholar Rock, Inc. Isoform-selective TGFβ1 inhibitors and use thereof
EP3820896A1 (en) * 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
CR20210416A (es) 2019-01-30 2021-09-14 Scholar Rock Inc INHIBIDORES ESPECIFICOS DEL COMPLEJO DE LTBP DE TGFß Y USOS DE LOS MISMOS
JPWO2021079958A1 (es) * 2019-10-25 2021-04-29
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
TW202241955A (zh) * 2021-01-18 2022-11-01 大陸商上海濟煜醫藥科技有限公司 Ｇａｒｐ蛋白抗體及其應用
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
EP4410840A4 (en) * 2021-09-30 2025-09-03 Betta Pharmaceuticals Co Ltd BISPECIFIC ANTIBODY AND ITS APPLICATION
TW202434643A (zh) * 2023-01-09 2024-09-01 大陸商北京拓界生物醫藥科技有限公司 ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途
CN118829657A (zh) * 2023-02-06 2024-10-22 贝达药业股份有限公司 多特异性抗体及其应用
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279508T3 (es) 1992-11-13 2007-08-16 Immunex Corporation Ligando elk, una citoquina.
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
EP0756627A1 (en) 1994-04-15 1997-02-05 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
DE122010000048I1 (de) 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
JP4587626B2 (ja) 1999-06-07 2010-11-24 イミュネックス・コーポレーション Ｔｅｋアンタゴニスト
AU779892B2 (en) 1999-08-27 2005-02-17 European Molecular Biology Laboratory Modified adenoviral fibre and uses thereof
NZ521437A (en) 2000-02-25 2004-04-30 Immunex Corp Integrin antagonists suitable as inhibitors of angiogenesis
ATE494304T1 (de) * 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
PT2295081T (pt) 2001-06-26 2019-02-01 Amgen Inc Anticorpos contra opgl
JP4761710B2 (ja) 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
CN105085678B (zh) * 2004-12-21 2019-05-07 阿斯利康公司 血管生成素-2的抗体及其应用
WO2007014162A2 (en) * 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2011145629A2 (ja) * 2010-05-18 2011-11-24 株式会社医学生物学研究所 形質転換増殖因子アルファに結合し、Ras遺伝子変異癌に対して増殖抑制活性を有する抗体
US20150290316A1 (en) * 2012-10-02 2015-10-15 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
HRP20251426T1 (hr) * 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
AU2014298373B2 (en) * 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
EP3139957A4 (en) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016164468A2 (en) * 2015-04-07 2016-10-13 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to adamts13 and uses thereof
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
BR112018068340A2 (pt) * 2016-03-11 2019-01-15 Scholar Rock Inc imunoglobulinas de ligação ao tgfss1 e usos destas

Also Published As

Publication number Publication date
JP2022153406A (ja) 2022-10-12
EP3484499A1 (en) 2019-05-22
JP7128801B2 (ja) 2022-08-31
WO2018013939A1 (en) 2018-01-18
CN110049773A (zh) 2019-07-23
SG11201900200XA (en) 2019-02-27
MA45690A (fr) 2019-05-22
CA3030862A1 (en) 2018-01-18
IL264161A (en) 2019-02-28
JP2019524094A (ja) 2019-09-05
IL264161B2 (en) 2025-06-01
IL264161B1 (en) 2025-02-01
BR112019000621A2 (pt) 2019-04-24
US20190292254A1 (en) 2019-09-26
AU2017294772A1 (en) 2019-01-31
US12281159B2 (en) 2025-04-22
MX2019000514A (es) 2019-07-12
EP3484499A4 (en) 2020-05-13
KR102577551B1 (ko) 2023-09-11
KR20190034560A (ko) 2019-04-02
US20210277100A1 (en) 2021-09-09
AU2017294772B2 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
MX419976B (es) Anticuerpos de tgfb, métodos, y usos
CR20170079A (es) Agentes de unión a cd123 y usos de estos
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
SV2018005634A (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y usos de estos
CO2019000931A2 (es) Polipéptidos modificados y usos de los mismos
AR134186A2 (es) Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
ECSP18040535A (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
CO2017010502A2 (es) Receptores del antígeno quimérico dirigidos al antígeno de maduración de células b
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
CL2017002728A1 (es) Método para el tratamiento de cáncer
MX2022004082A (es) Anticuerpos biespecificos contra cd3 y cd20.
CR20170326A (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
UY37523A (es) Anticuerpos anti-ox40 y sus usos
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
TWD170353S (zh) 項鍊
UY35965A (es) Anticuerpos humanos contra pd?l1
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2017001402A (es) Constructos de anticuerpos para cdh19 y cd3.
MX2016015952A (es) Constructos de anticuerpo multiespecifico.
MX2017003784A (es) Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos.
PH12018501902A1 (en) Gitr antibodies, methods, and uses
UY35835A (es) Anticuerpos específicos para FcRn.